Keyword: Boehringer Ingelheim
Domain Therapeutics has another big pharma partner, signing a deal with Boehringer Ingelheim to develop new drugs for CNS disorders.
In a collaboration worth up to $300 million or more, Boehringer Ingelheim tapped Epizyme to help research two regulators of genes linked to cancer.
Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.
The takeover is focused on VSV candidates Boehringer sees becoming key components of its efforts to gain ground in the immuno-oncology sector.
Different KRAS mutations exert diverging effects on protein function, a new study illustrates.
Boehringer will work with British academics and Oxford BioMedica to develop an inhaled, lentiviral vector-based gene therapy for cystic fibrosis.
NBE will use the money to start testing anti-ROR1 antibody-drug conjugate NBE-002 in solid tumor patients.
Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.